923 results about "Methyl Donors" patented technology

The invention provides an UTR element NHP1 as well as a construction method and application thereof, and relates to the technical field of mRNA. A 5 'UTR with a good expression effect is designed by integrating dominant sequences of a human high-expression gene and a pathogen natural UTR, a chimeric structure NHP1 with high ribosome load is predicted through a calculation model, a DNA sequence of the NHP1 is as shown in SEQ NO 1, and an RNA sequence of the NHP1 is as shown in SEQ NO 2; an EGFP report system is adopted on the DNA level to rapidly screen UTR; the translation efficiency is quantitatively evaluated on the RNA level through luciferase mRNA (N1-methyl pseudouridine modification); and the particle size is controlled by a microfluidic technology, so that the optimized UTR-mRNA is efficiently expressed after being delivered.

The invention relates to hydrogel loaded with oxygen self-producing nanoparticles as well as a preparation method and application of the hydrogel. The preparation method comprises the following steps: 1, taking cross-linked methacrylamide silk fibroin and hyaluronic acid modified by arginine-glycine-aspartic acid peptide as base materials, and loading self-oxygen-producing nano particles CaO2 (at) PVP (at) Cu-EGCG, and the self-oxygen-producing nano particles CaO2 (at) PVP (at) Cu-EGCG are prepared by coating Cu-EGCG on calcium peroxide nano particles modified by PVP modified polyvinylpyrrolidone. The hydrogel can improve energy metabolism and regulate immune environment through dual mechanisms, realizes efficient promotion of myocardial repair, and provides a new strategy and thought for tissue regeneration and functional recovery after myocardial infarction.

The invention discloses an ovarian protection composition containing ergothioneine and a preparation method of the ovarian protection composition, and relates to the technical field of ovarian protection compositions. The ovary protection composition containing the ergothioneine is prepared from the following components in parts by mass: 0.1 to 0.5 part of the ergothioneine, 0.05 to 1 part of S-equol, 1 to 5 parts of reducing coenzyme Q10, 1 to 3 parts of vitamin E, 10 to 20 parts of chitosan oligosaccharide, 30 to 50 parts of microcrystalline cellulose, 3 to 8 parts of hydroxypropyl methyl cellulose, 0.5 to 2 parts of silicon dioxide and 0.5 to 2 parts of a stabilizer. By adopting the stabilizer, photooxidation and hydrolysis of sensitive components are inhibited through molecular action, and the long-term stability of the composition in a humid and hot environment is remarkably improved in combination with the physical barrier action of silicon dioxide. Through the antioxidant synergistic effect of the ergothioneine and the vitamin E, the hormone regulation effect of the S-equol and the energy metabolism improvement effect of the coenzyme Q10, a multi-layer ovarian function protection system is constructed, and the health state of ovaries is improved. Through a special process, the tablet can be rapidly disintegrated and slowly released in an intestinal targeted manner, burst release of active ingredients is avoided, and the absorption efficiency is improved.

The invention belongs to the technical field of dressing preparation, and particularly relates to a preparation method of a photocuring methacrylated gelatin hydrogel dressing, which comprises the following steps: step 1, dissolving methacrylated gelatin in a phosphate buffer solution to prepare a methacrylated gelatin solution with the mass concentration of 5-15%; 2, adding a natural photoinitiator into the solution obtained in the step 1, and uniformly stirring and mixing; 3, adding the traditional Chinese medicine active ingredient powder, and stirring until the powder is uniformly dispersed to obtain a mixed solution; and 4, pouring the mixed solution into a mold, and curing and molding under the irradiation of visible light. Chlorophyll or riboflavin is used as a natural photoinitiator and is directly dispersed in a methacrylated gelatin solution in a physical blending mode, a curing light source enables chlorophyll to completely avoid a chemical initiator, meanwhile, the process is simplified into physical stirring to replace nanoparticle synthesis and modification, visible light reduces the risk of tissue burn, the production cost is reduced, and the method is suitable for industrial production. The method is suitable for primary medicine.

The present disclosure relates to pharmaceutically acceptable salts, cocrystals, and crystalline forms thereof, of a compound which is N—((S)-1-(3-(4-chloro-3-(methylsulfonamido)-1-(2,2,2-trifluoroethyl)-1H-indazol-7-yl)-6-(3-methyl-3-(methylsulfonyl)but-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2- ((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-TH-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide, which is useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus.

The invention belongs to the technical field of polyether refining, and particularly relates to a methyl-terminated polyether refining treatment method. Comprising the following steps: adding water into a to-be-refined methyl-terminated polyether sample, stirring, dissolving salt in water, layering, adding water into a polyether layer again after separation, stirring, layering, and separating to obtain a primary sample; taking a methyl-terminated polyether sample to be refined again, heating, adding water, adjusting the pH with acid, and stirring to obtain a sample A; adding the preliminary sample into the sample A, and stirring to obtain a sample B; and adding acid into the sample B to adjust the pH value, continuously stirring, crystallizing the metal salt into large particles, settling, separating out solids, deacidifying and decolorizing, dehydrating in vacuum, and filtering to obtain qualified methyl-terminated polyether products, and intercepting part of qualified products as preliminary samples for continuous production. By adding the methyl-terminated polyether primary finished product, the crystallization process of the metal salt can be effectively improved, so that the metal salt tends to generate coarse particles easy to filter, the filtering resistance is reduced, and the filtering period is shortened.

The invention relates to a high-water-solubility denitroflavin covalent complex as well as a preparation method and application thereof, and belongs to the technical field of organic synthesis and medicinal chemistry. Comprising the following steps: (1) firstly, carrying out bromination reaction on 3-methyl-10-ethyl denitroflavin, so as to obtain 3-methyl-10-(1-bromoethyl) denitroflavin; and (2) coupling the 3-methyl-10-(1-bromoethyl) denitroflavin with vitamin C, so as to obtain the high-water-solubility denitroflavin covalent complex. According to the present invention, the prepared highly water-soluble denitrificin covalent complex has the two-phase solubility of the organic solvent and the water, such that the water solubility of the 3-methyl-10-ethyl-denitrificin is substantially enhanced, and the application range of the denitrificin is expanded. And meanwhile, the denitrified flavin covalent compound also has good antioxidant activity, and the antioxidant duration can be prolonged.

Described herein are pharmaceutical formulations of a farnesoid X receptor agonist, 4-((4-(1-(tert-butyl)-1H-pyrazol-4-yl)pyridin-2-yl)((4-(4-methoxy-3-methylphenyl)bicyclo[2.2.2]octan-1-yl)methyl)carbamoyl)cyclohexyl 3-hydroxyazetidine-trans-1-carboxylate, and methods of using such pharmaceutical formulations in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.

Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof. Another method includes: administering once-daily to the subject in need thereof, an oral load dose formulation having from 240 mg to 480 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof, and thereafter administering once-daily to the subject, an oral maintenance dose formulation having 80 mg to 160 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.

The invention belongs to the technical field of biological detection, and particularly relates to a method for synchronously and quantitatively detecting various folic acid metabolism related substances in trace plasma or serum, which comprises the following steps of: detecting a pretreated trace plasma or serum sample by adopting a liquid chromatography-tandem mass spectrometry method; the following nine folic acid metabolism related substances are synchronously and quantitatively detected: 5-formyl tetrahydrofolic acid, folic acid, 5-methyl tetrahydrofolic acid, S-adenosine-L-methionine, S-adenosine-L-homocysteine, vitamin B12, pyridoxamine, pyridoxine and pyridoxal. The invention further relates to application of the detection method in related detection of child neurodevelopment. According to the detection method, only trace plasma or serum is used, methotrexate is used for replacing an expensive isotope internal standard for more economical detection, and nine folate metabolism related substances can be accurately quantified at the same time. Therefore, the detection method disclosed by the invention has important clinical significance and wide market application prospect.

The invention discloses a photocuring microneedle with ginseng exosome loaded berberine, a preparation method of the photocuring microneedle and application of the photocuring microneedle to tissue repair. A ginseng exosome loaded berberine compound is prepared through a microfluidic technology; filling a needle cavity of a microneedle mold with a needle tip layer preparation solution containing the compound, methylacryloylated hyaluronic acid and methylacryloylated gelatin through a centrifugal method; covering a backing layer preparation solution composed of hyaluronic acid and povidone K90, and centrifuging again; and finally, carrying out light curing, drying and demolding. The prepared composite microneedle is complete and sharp in needle shape and high in forming rate; the efficient entrapment of the active medicine is realized; the biocompatibility is good, and the irritation is low; a cross-linked network structure formed by photocuring is beneficial to realizing controlled release of drugs, the targeted repair function of the ginseng exosome is combined with the hypoglycemic effect of berberine, and a new strategy and technical approach with a prospect are provided for painless, efficient and long-acting treatment of diabetes mellitus.

In some aspects, the present disclosure pertains to systems for forming hydrogels that comprise (a) a radiopaque polyamino compound and (b) a reactive polymer comprising a plurality of hydrophilic polymer segments and a plurality of reactive moieties, wherein the reactive moieties are reactive with amino groups of the radiopaque polyamino compound, and wherein the radiopaque polyamino compound is produced by a method that comprises: (i) converting hydroxyl groups of a polyhydroxylated radiopaque compound to amino groups, (ii) converting vicinal diol groups (—CHOHCH2OH groups) of a polyhydroxylated radiopaque compound into hydroxyaminoethyl groups (—CHOHCH2NH2 groups), or (iii) converting vicinal diol groups of a polyhydroxylated radiopaque compound into aminomethyl groups (—CH2NH2 groups). In other aspects, the present disclosure pertains to hydrogels formed from such systems and to methods of treatment using such systems.

The invention relates to the technical field of biomedical materials, in particular to photo-thermal antibacterial healing-promoting hydrogel as well as a preparation method and application thereof. The preparation method of the hydrogel comprises the following steps: dispersing mesoporous polydopamine (MPDA) into a Tris-HCl solution, and then adding L-arginine to prepare L-MPDA; the preparation method comprises the following steps: fully dissolving 3-(aminomethyl) phenylboronic acid hydrochloride and 4-(4, 6-dimethoxytriazine-2-yl)-4-methylmorpholine hydrochloride into hyaluronic acid (HA), regulating the pH value to 6.5 by using alkali liquor to obtain phenylboronic acid modified hyaluronic acid mixed liquor, and dialyzing and freeze-drying to obtain HA-PBA. The preparation method comprises the following steps: dissolving metformin and purified L-MPDA in deionized water, sequentially adding purified HA-PBA and a polyvinyl alcohol (PVA) solution, and uniformly mixing to obtain the hydrogel. The hydrogel prepared by the invention has excellent hemostasis, antibacterial and adhesion properties. When the hydrogel is used as a hydrogel dressing for treating a diabetic wound surface, the healing speed of the diabetic wound surface can be effectively improved.

The present invention is directed to substituted 1-(1H-imidazol-1-yl)-3-methyl-2- phenylbutan-2-ol and 1-cyclopentyl-2-(1H-imidazol-1-yl)-1-phenylethan-1-ol compounds useful as agonists of 8-oxo-guanine DNA glycosylase (OGG1) in humans, as well as pharmaceutical compositions comprising them and methods of their use in treating diseases, including metabolic syndrome, obesity, fatty liver disease, dyslipidemia, insulin resistance, neurodegenerative disorders and cancers.

In the first aspect, the present disclosure provides a Lactoferrin polypeptide fragment, where the Lactoferrin polypeptide fragment has an amino acid sequence shown in SEQ ID NO: 1. In the second aspect, the present disclosure provides a preparation method of the Lactoferrin polypeptide fragment, including: protecting amino acids using a 9-fluorenylmethoxycarbonyl (Fmoc) protecting group, coupling the amino acids with a P-hydroxymethylphenoxymethyl polyethylene resin (HMP resin) in an order of cysteine, alanine, leucine, cysteine, glutamate, threonine, asparagine, aspartate, asparagine, phenylalanine, leucine, leucine, asparagine, and lysine, and separating the HMP resin to obtain a target Lactoferrin polypeptide fragment. In the third aspect, the present disclosure further provides an anti-Lactoferrin antibody prepared using the Lactoferrin polypeptide fragment, and use of the Lactoferrin polypeptide fragment in preparation of an anti-Lactoferrin flow cytometric antibody and in preparation of a Lactoferrin detection product.

The invention discloses an electrochemical urine biopsy system for cathepsin B analysis and a detection method of the electrochemical urine biopsy system. The electrochemical urine biopsy system comprises gold nanoparticles AuNPs, a peptide-peptide nucleic acid PNA series probe and an electrochemical sensor. The peptide-peptide nucleic acid tandem probe is combined with gold nanoparticles through a mercaptan modified sequence to form a spherical nanostructure with the diameter of 15 nm, a polypeptide substrate sequence serves as a specific reaction substrate of cathepsin B, and PNA provides stability and a signal shielding function. The electrochemical sensor is based on a cutting enzyme-assisted DNAwalker mechanism, signal amplification is started through methylene blue MB release, and high-sensitivity detection of the released PNA probe is achieved. The system provided by the invention has the characteristics of high specificity, high sensitivity and rapid response, can realize quantitative analysis of cathepsin B through noninvasive urine biopsy, and provides a new technical means for early diagnosis and treatment monitoring of tumors.

Methods for treating patients with wAIHA comprising administering at least one compound chosen from (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (rilzabrutinib) and pharmaceutically acceptable salts thereof are disclosed.

The invention discloses a urine microalbumin immunoturbidimetry kit and a detection method, and belongs to the technical field of biology. The invention relates to a urine microalbumin immunoturbidimetry kit, which comprises a reagent R1, a reagent R2, a reagent R3 and a reagent R4, wherein the reagent R1 comprises trihydroxymethyl aminomethane, a coagulant, a blocking agent, sodium chloride, bovine serum albumin, trehalose, a preservative and ultrapure water; the reagent R2 is prepared from hydroxyethyl piperazine ethanesulfonic acid, sodium chloride, bovine serum albumin, glycerol, trehalose, a preservative, a mALB monoclonal antibody and ultrapure water; the mALB monoclonal antibody is prepared by mixing a model number of UDA 9107-1, a model number of UDA 9107-2, a model number of UDA 9107-3 and a model number of UDA 9107-4 according to a mass ratio of (0.8 to 1.2): (0.8 to 1.2): (0.8 to 1.2): (0.8 to 1.2). A mixed antibody of four mALB monoclonal antibodies is specifically combined with a urine microalbumin antigen in a sample to form an antigen-antibody compound, and the antigen-antibody compound has high specificity and high sensitivity; the method has a relatively high detection range, can effectively avoid a hook effect of an ultrahigh-value sample, and can realize rapid and convenient automatic detection.

The invention provides a programmable hydrogel wound dressing with rotation contraction force and application thereof, and belongs to the technical field of biomedical materials, the programmable hydrogel wound dressing comprises a dual-network hydrogel main body, a first hydrogel layer, a second hydrogel layer, a first hydrogel layer and a second hydrogel layer, and the dual-network hydrogel main body is composed of a first network and a second network; the first network is a chemically cross-linked methacrylated hyaluronic acid network and forms a cross-linked network structure through photopolymerization; the second network is a physical cross-linked polyvinyl alcohol network, and forms an instantaneous cross-linking point with a crystal region through a hydrogen bond, so that the hydrogel is endowed with shape memory performance; the surface is modified with an N-hydroxysuccinimide ester functional group, and the N-hydroxysuccinimide ester functional group and amino of wound tissue protein can form a covalent bond; the dual-network hydrogel main body is subjected to pre-stretching or pre-twisting treatment and then is dried and shaped into a preset shape, the initial shape is recovered after moisture is absorbed, and rotary contraction mechanical force is output. Rapid wound healing and scar-free regeneration are achieved by dynamically regulating and controlling wound edge mechanical force and enhancing tissue adhesion, and then application to regulation and control of wound microenvironment to promote scar-free healing is achieved.

The invention relates to a detection kit for combined methylmalonemia, which is a cb1C type kit and comprises a specific primer pair and a probe combination for detecting at least one mutation site of MMACHC, the mutation site is selected from c.609Ggt; a is c.567 dupT, c.658660delAAG, c.482Ggt, and c.482Ggt; a, c.1Agt; g, c, 80Agt; g, c, 217Cgt; 315Cgt, T, c.315Cgt; g and c.394 Cgt; t). The MMACHC gene hotspot mutation region detection kit based on the real-time fluorescent quantitative PCR technology can detect multiple mutation sites on the MMACHC gene at the same time, detection of three genotypes of wild type, homozygous mutant type and heterozygous mutant type on each mutation site is completed, the gene detection requirements of clinical combined type MMA are effectively met, the detection time is shortened, and the detection efficiency is improved. The mutation site coverage rate of CblC defective methylmalonic acidmia combined with homocysteinemia on the MMACHC gene is increased to 93.28%, mutation hot spots of most people are covered, and various types of mutation conditions in hot spot mutation areas can be rapidly, accurately and sensitively detected.

The application relates to a cartilage organoid based on a DNA-silk fibroin hybrid hydrogel sustained-release system and a preparation method and application thereof. The DNA-silk fibroin hybrid hydrogel sustained-release system is a hydrogel system after a DNA-silk fibroin hybrid hydrogel sustained-release system premixing solution is printed through a digital light processing system, wherein the DNA-silk fibroin hybrid hydrogel sustained-release system premixing solution contains DNA, silk fibroin, acrylated RGD peptide, acrylated polyethylene glycol NHS ester, glucosamine, TD-198946 and 2,4,6-trimethylbenzoyl lithium phosphate. Compared with the prior art, the glucosamine and TD-198946 introduced in the DNA-silk fibroin hybrid hydrogel sustained-release system can significantly improve the cartilage differentiation efficiency of bone marrow mesenchymal stem cells; and the application can be transplanted to a cartilage defect as a cartilage graft to promote cartilage regeneration and repair.

Described herein is the farnesoid X receptor agonist, 4-((4-(1-(tert-butyl)-1H-pyrazol-4-yl)pyridin-2-yl)((4-(4-methoxy-3-methylphenyl)bicyclo[2.2.2]octan-1-yl)methyl)carbamoyl)cyclohexyl 3-hydroxyazetidine-trans-1-carboxylate, including crystalline forms and pharmaceutically acceptable salts, solvates, and formulations thereof.

The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.

The invention discloses a compound rumen bypass guanidinoacetic acid additive as well as a preparation method and application thereof, and belongs to the technical field of animal feed additives. The compound rumen bypass guanidinoacetic acid additive provided by the invention is prepared from the following components in parts by mass: 40 to 60 parts of guanidinoacetic acid, 0.1 to 0.5 part of selenium yeast, 5 to 10 parts of nicotinamide, 5 to 12 parts of DL-methionine, 0.01 to 0.05 part of vitamin B12, 1 to 3 parts of compound probiotics, 3 to 5 parts of hydroxypropyl methyl cellulose, 1 to 2 parts of ethyl cellulose, 15 to 25 parts of hydrogenated palm oil and 3 to 5 parts of glyceryl monostearate. The compound probiotics comprise bacillus subtilis and saccharomyces cerevisiae. The compound additive provided by the invention can significantly improve the daily gain of ruminants and reduce the feed-gain ratio, and meanwhile, due to the improvement of the energy utilization efficiency and the enhancement of the antioxidant ability, the immunity of animals is improved, the morbidity is reduced, and the meat quality is improved.

The invention discloses a tellurium-doped carbon quantum dot and a preparation method and application thereof, the tellurium-doped carbon quantum dot is obtained by using 2, 2 '-diaminodiphenyl telluride as a precursor, the average particle size is 1.9 nm, the thickness is about 2.1 nm, and the surface is rich in amino groups. And fixing (4-carboxybutyl) triphenylphosphonium bromide, 3-morpholinopropionic acid or 3-((4-methylphenyl) sulfonamide) propionic acid on the surfaces of the tellurium-doped carbon quantum dots to prepare Mito-Te-CDs, Lyso-Te-CDs and ER-Te-CDs with an organelle targeting function. The Mito-Te-CDs, the Lyso-Te-CDs and the ER-Te-CDs are good in biocompatibility, can be used as fluorescent probes for targeted imaging of organelles, can be used for recognition and removal of superoxide anions in specific organelles, have a protection effect on cells and can be used for effectively treating acute kidney injury.

The present invention belongs to the technical field of rapid detection of drug sensitivity for bacteria. Disclosed are an enrichment culture medium, and a preparation method therefor and the use thereof. The enrichment culture medium comprises the following raw materials in parts by mass: 15.0-20.0 parts of tryptone, 3.5-5.5 parts of peptone, 1.5-3.5 parts of glucose, 5.0-6.5 parts of yeast extract, 2.0-2.5 parts of dipotassium phosphate, 2.0-3.5 parts of disodium hydrogen phosphate, 1.0-1.5 parts of monopotassium phosphate, 2.5-7.5 parts of sodium chloride, 12.0-18.0 parts of proteose peptone, 15.0-22.0 parts of beef heart infusion powder, 8.0-12.0 parts of soya peptone, 1.0-5.0 parts of 0.1% nicotinamide adenine dinucleotide (NAD), 30-100 parts of newborn calf serum inactivated at 56°C for 30 min, 2.0-4.0 parts of mannitol, 3.0-5.0 parts of sodium pyruvate, 0.23-0.45 parts of cycloheximide, 0.8-2.0 parts of 0.05% bromothymol blue, 2.5-4.5 parts of 0.1% methylene blue, and 1000 parts of distilled water, with the pH value of 6.8-7.5. The enrichment culture medium is used to screen effective therapeutic drugs for bacterial diseases in poultry, and is convenient to use and has a single enrichment effect superior to that of respective selective enrichment broths of target bacteria. Therefore, the culture medium can realize rapid proliferation of common pathogenic bacteria in poultry.

The present application discloses an antibacterial hydrogel dressing with integrated constant temperature photothermal effect and controlled drug release function, as well as its preparation method and application, which belongs to the field of medical biomaterial technology. The antibacterial hydrogel dressing with integrated constant temperature photothermal effect and controlled drug release function provided by the present application includes: a dressing and an antibiotic drug compounded on the dressing; the dressing is woven from photothermal water gel fiber and thermosensitive hydrogel fiber; the photothermal water gel fiber is made of photothermal dye, proton donor and phase change material as the core layer and sodium alginate as the shell layer; the thermosensitive hydrogel fiber is made of N-isopropyl acrylamide, methylene bisacrylamide, phenyl-2,4,6-trimethylbenzoyl lithium phosphinate and sodium alginate. The hydrogel dressing prepared by the present application has an inherent temperature control mechanism, can release drugs on demand and in a concentrated manner, has excellent antibacterial effect, and has broad application prospects in the preparation of biomedical materials.

The invention discloses a thiochromanone derivative containing a thiosemicarbazone structure and application of the thiochromanone derivative, relates to the technical field of medicines, and particularly relates to the technical field that the compound has better oxidation resistance and alpha-glucosidase resistance activity, the IC50 value of the compound 1-(7-chloro-4, 4-dioxothiochromanone-3-N-propyl) thiosemicarbazone to ABTS clearance activity is 2.86 [mu] g / mL, the IC50 value of the compound 1-(7-chloro-4, 4-dioxothiochromanone-3-N-propyl) thiosemicarbazone to alpha-glucosidase inhibition activity is 9.51 [mu] g / mL, and the effect is the best and is superior to that of a control agent vitamin E and acarbose. The thiochromanone derivative containing the thiosemicarbazone structure has a general formula shown in the specification,

The invention discloses an ergothioneine-producing recombinant engineering bacterium as well as a construction method and application thereof, and belongs to the technical field of gene recombination fermentation. The method comprises the following steps: by taking escherichia coli as a starting bacterium, carrying out recombinant expression on a histidine trimethyl inner salt cysteine sulfoxide synthetase egt1 gene, an L-histidine methyltransferase egtD gene, a histidine trimethyl inner salt cysteine sulfoxide lyase egt2 gene, a methionine adenosine transferase metK gene, an adenylate kinase adK gene and an adenine phosphoribose transferase apt gene; on this basis, supply of precursor substances including histidine, cysteine and methionine is further improved through metabolic transformation, the yield of the finally obtained recombinant engineering bacterium for producing ergothioneine reaches 2.54 g / L after 48 h of shake-flask culture, the yield of a 5L fermentation tank reaches 18 g / L after further enlarged culture, the yield of ergothioneine is guaranteed while energy consumption and cost are reduced, and the method is suitable for industrial production. The method is suitable for practical popularization.

The present invention relates to salts of aminopyrimidine compounds and uses thereof. In particular, the present invention relates to salts of (S)-2-(1-((6-amino-5-(3-methyl-1,2,4-oxadiazol-5-yl)pyrimidin-4-yl)amino)ethyl)-5-(3-hydroxyprop-1-yn-1-yl)-3-phenylquinazolin-4(3H)-one and pharmaceutical compositions comprising said salts, further to their use in the manufacture of a medicament for the treatment and prevention of diseases associated with PI3K kinase abnormalities.